Powder: -20°C for 3 years | In solvent: -80°C for 1 year
Bozitinib (PLB-1001) (PLB-1001) is a highly selective inhibitor of the c-MET kinase with blood-brain barrier permeability. Bozitinib binds to the conventional ATP-binding pocket of the tyrosine kinase superfamily.
Pack Size | Availability | Price/USD | Quantity |
---|---|---|---|
1 mg | In stock | $ 135.00 | |
5 mg | In stock | $ 289.00 | |
10 mg | In stock | $ 455.00 | |
25 mg | In stock | $ 753.00 | |
50 mg | In stock | $ 1,060.00 | |
100 mg | In stock | $ 1,430.00 | |
1 mL * 10 mM (in DMSO) | In stock | $ 317.00 |
Description | Bozitinib (PLB-1001) (PLB-1001) is a highly selective inhibitor of the c-MET kinase with blood-brain barrier permeability. Bozitinib binds to the conventional ATP-binding pocket of the tyrosine kinase superfamily. |
In vitro | Bozitinib (30 μM; 6 hours) inhibits the phosphorylation of MET and STAT3. Bozitinib has a robust inhibitory effect on MET and its downstream signaling pathways. |
Synonyms | CBT-101, PLB-1001 |
Molecular Weight | 424.38 |
Formula | C20H15F3N8 |
CAS No. | 1440964-89-5 |
Powder: -20°C for 3 years | In solvent: -80°C for 1 year
DMSO: 47 mg/mL (110.74 mM), sonification is recommended.
You can also refer to dose conversion for different animals. More
bottom
Please see Inhibitor Handling Instructions for more frequently ask questions. Topics include: how to prepare stock solutions, how to store products, and cautions on cell-based assays & animal experiments, etc.
Bozitinib 1440964-89-5 Tyrosine Kinase/Adaptors c-Met/HGFR CBT-101 PLB1001 Vebreltinib CBT 101 inhibit PLB-1001 CBT101 PLB 1001 Inhibitor inhibitor